About Remedy Plan
Remedy Plan is a company founded in 2011. It operates as a HealthTech. Remedy Plan has raised $24.7 million across 3 funding rounds from investors including ARE and Schooner Capital. Remedy Plan offers products and services including RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug. Remedy Plan operates in a competitive market with competitors including Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others.
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$24.7 M (USD)
in 3 rounds
-
Latest Funding Round
$18 M (USD), Series B
May 13, 2025
-
Investors
ARE
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Remedy Plan
Remedy Plan offers a comprehensive portfolio of products and services, including RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A novel NAMPT inhibitor for oncology treatment is developed.
A NAMPT inhibitor for autoimmune diseases is being researched.
A NAMPT inhibitor for obesity treatment is under development.
Unlock access to complete
Unlock access to complete
Funding Insights of Remedy Plan
Remedy Plan has successfully raised a total of $24.7M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $18 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $18.0M
-
First Round
First Round
(09 Nov 2018)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Series B - Remedy Plan | Valuation |
investors |
|
| Dec, 2019 | Amount | Series A - Remedy Plan | Valuation |
investors |
|
| Nov, 2018 | Amount | Series A - Remedy Plan | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Remedy Plan
Remedy Plan has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE and Schooner Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed across multiple sectors.
|
Founded Year | Domain | Location | |
|
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Remedy Plan
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Remedy Plan
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Remedy Plan Comparisons
Competitors of Remedy Plan
Remedy Plan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Moderna, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Remedy Plan
When was Remedy Plan founded?
Remedy Plan was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Is Remedy Plan a funded company?
Remedy Plan is a funded company, having raised a total of $24.7M across 3 funding rounds to date. The company's 1st funding round was a Series A of $1.5M, raised on Nov 09, 2018.
What does Remedy Plan do?
Remedy Plan is engaged in the development of innovative therapeutics targeting NAMPT, a key regulator of cellular energy metabolism. The companys efforts are directed towards addressing diseases in oncology, autoimmune disorders, and metabolic conditions. A proprietary drug screening platform is utilized to discover and optimize drugs, with their lead candidate RPT1G advancing in clinical trials for oncology. Solutions are being explored to overcome historical toxicity challenges in NAMPT inhibition, offering potential treatments across multiple health sectors.
Who are the top competitors of Remedy Plan?
Remedy Plan's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Remedy Plan offer?
Remedy Plan offers RPT1G, NAMPT Autoimmune Drug, and NAMPT Obesity Drug.
Who are Remedy Plan's investors?
Remedy Plan has 2 investors. Key investors include ARE, and Schooner Capital.